 |
 |
|
1 December 1996 | Volume 125 Issue 11 | Page 940
A 17-year-old healthy girl presented to the hospital after a suicidal ingestion of 13 g of Extended-Relief Tylenol (McNeil Consumer Products Co., Fort Washington, Pennsylvania). She was asymptomatic, and vital signs and physical examination findings were normal. Acetaminophen levels were obtained 3 hours and 5 hours after ingestion. Both values were below the Rumack-Matthew nomogram (Figure 1). While the patient awaited psychiatric consultation, the acetaminophen level was measured for the third time 11 hours after ingestion. The level was 79.8 µg/mL and was in the toxic range when plotted on the nomogram. Oral N-acetylcysteine therapy was begun, and the patient received the standard 72-hour regimen. Liver function test results were monitored every 12 hours and remained normal for the next 89 hours. Results of serum and urine toxicology screens were negative. LETTER
Use of the Rumack-Matthew Nomogram in Cases of Extended-Release Acetaminophen Toxicity
TO THE EDITOR:
|
Extended-relief acetaminophen is available in 650-mg caplets intended to release 325 mg immediately and 325 mg more slowly. Although a few published case reports have described acetaminophen overdose [1, 2], it is unclear how and whether the different toxicokinetics of extended-relief acetaminophen will affect use of the Rumack-Matthew nomogram.
What does the nomogram line represent? Does it indicate the total area under the curve, and is this the important factor in the development of toxicity? Is it some threshold serum value that, when surpassed, results in saturation of sulfation and glucuronidation and depletion of glutathione? Prescott and colleagues' report [3] of hepatic failure in untreated acetaminophen overdoses showed early prolongation of apparent acetaminophen half-lives before hepatotoxicity occurred, probably as a result of saturation pharmacokinetics. Late crossing of the nomogram line after a single acute overdose of extended-relief acetaminophen may simply reflect slow ongoing absorption rather than saturation pharmacokinetics. Unless some threshold value has been reached, toxicity might be unlikely. Further research and a thoughtful rational approach to acetaminophen overdose is needed.
Author and Article Information
|
|---|
 Top Author & Article Info References |
|---|
References
|
|---|
|
TopAuthor & Article InfoReferences |
|---|
1. Cetaruk EW, Dart RC, Horowitz RS, Hurlbut KM. Extended-release acetaminophen overdose [Letter]. JAMA. 1996; 275:686.
2. Graudins A, Aaron CK, Linden CH. Overdose of extended-release acetaminophen [Letter]. N Engl J Med. 1995; 333:196.
3. Prescott LF, Wright N, Roscode P, Brown SS. Plasma-paracetamol half-life and hepatic necrosis in patients with paracetamol overdose. Lancet. 1971; 1:519-22.
About Letters
 |
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
This article has been cited by other articles:
|
|
 |
|
  J. Boullata Natural Health Product Interactions with Medication Nutr Clin Pract, February 1, 2005; 20(1): 33 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. H Halsted Dietary supplements and functional foods: 2 sides of a coin? Am. J. Clinical Nutrition, April 1, 2003; 77(4): 1001S - 1007. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Skinner and J. Rangasami Preoperative use of herbal medicines: a patient survey Br. J. Anaesth., November 1, 2002; 89(5): 792 - 795. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Wooltorton Herbal kava: reports of liver toxicity Can. Med. Assoc. J., March 1, 2002; 166(6): 777 - 777. [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Leung, S. Dzankic, K. Manku, and S. Yuan The Prevalence and Predictors of the Use of Alternative Medicine in Presurgical Patients in Five California Hospitals Anesth. Analg., October 1, 2001; 93(4): 1062 - 1068. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. Ang-Lee, J. Moss, and C.-S. Yuan Herbal Medicines and Perioperative Care JAMA, July 11, 2001; 286(2): 208 - 216. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. Kessler, J. Soukup, R. B. Davis, D. F. Foster, S. A. Wilkey, M. I. Van Rompay, and D. M. Eisenberg The Use of Complementary and Alternative Therapies to Treat Anxiety and Depression in the United States Am J Psychiatry, February 1, 2001; 158(2): 289 - 294. [Abstract] [Full Text]
|
|
|
|
 |
|
 G. Beaubrun and G. E. Gray A Review of Herbal Medicines for Psychiatric Disorders Psychiatr Serv, September 1, 2000; 51(9): 1130 - 1134. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. C. LaFrance Jr., E. C. Lauterbach, C. E. Coffey, S. P. Salloway, D. I. Kaufer, A. Reeve, D. R. Royall, E. Aylward, T. A. Rummans, and M. R. Lovell The Use of Herbal Alternative Medicines in Neuropsychiatry: A Report of the ANPA Committee on Research J Neuropsychiatry Clin Neurosci, May 1, 2000; 12(2): 177 - 192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bendich The Potential for Dietary Supplements to Reduce Premenstrual Syndrome (PMS) Symptoms J. Am. Coll. Nutr., February 1, 2000; 19(1): 3 - 12. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Gardiner and K. J. Kemper Herbs in Pediatric and Adolescent Medicine Pediatr. Rev., February 1, 2000; 21(2): 44 - 57. [Full Text]
|
|
|
|
 |
|
 A. Fugh-Berman and L. G. Miller Herbal Medicinals: Selected Clinical Considerations, Focusing on Known or Potential Drug-Herb Interactions Arch Intern Med, September 13, 1999; 159(16): 1957 - 1959. [Full Text] [PDF]
|
|
|
|
|
|
J. Yager, S. L. Siegfreid, and T. L. DiMatteo Use of Alternative Remedies by Psychiatric Patients: Illustrative Vignettes and a Discussion of the Issues Am J Psychiatry, September 1, 1999; 156(9): 1432 - 1438. [Full Text]
|
|
|
|
 |
|
 A. Fugh-Berman and J. M. Cott Dietary Supplements and Natural Products as Psychotherapeutic Agents Psychosom Med, September 1, 1999; 61(5): 712 - 728. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. G. Miller Herbal Medicinals: Selected Clinical Considerations Focusing on Known or Potential Drug-Herb Interactions Arch Intern Med, November 9, 1998; 158(20): 2200 - 2211. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Herbal Psychotropic Medications: Promises and Pitfalls Journal Watch Psychiatry, November 1, 1998; 1998(1101): 19 - 19. [Full Text]
|
|
|
|
 |
|
 L. S. Goldman Use of Herbal Medicines Among C-L Populations Psychosomatics, October 1, 1998; 39(5): 482 - 482. [Full Text]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
